ArticleBiochemistry and biophysics reports2025
Machine learning and WGCNA reveal the PVT1/miR-143-3p/CDK1 ceRNA axis as a key regulator in NSCLC.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Machine learning has provided novel tools for analysis of multi-omics data for subgroups recognition in cancer to reach a clinically meaningful classification of cancer and identification of potential biomarkers. In this work, we retrieved mRNA, lncRNA, miRNA and protein expression data of non-small cell lung cancer (NSCLC) samples and used different machine learning methods for biomarker selection, diagnostic validation, construction of competing endogenous RNA network, identification of the hub axes and drug prediction. Integration of multi-omics data and machine learning resulted in identification of CDK1, TOP2A, AURKA, TPX2, BUB1B, and CENPF as key biomarkers in NSCLC. We also identified the PVT1/miR-143-3p/CDK1 axis and its associated transcription factors (FOXC1, YY1, and GATA2) as a potential regulatory network for additional investigations. These findings increase the understanding of NSCLC molecular processes and provide a foundation for developing targeted therapies and diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.